Project Grant R21CA296234
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$420K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to define key components of the PRMT5 axis that impair cell viability upon PRMT5 inhibition and identify pathways that can restore viability in MTAP-deleted cancer cells. The $442,089 award to Yale University will leverage a genome-scale CRISPR activation platform to identify genes that modulate sensitivity to PRMT5 pathway inhibition. The research aims to...
This Project Grant award, totaling $486,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports research conducted by the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to target PRMT5 in MTAP-loss melanoma. The project aims to transform health care for Service Members and the public through innovative and impactful cancer research, with a focus on...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $542,663 to The University of Texas M.D. Anderson Cancer Center to conduct preclinical research on novel therapies for acute myeloid leukemia (AML). The research aims to evaluate the efficacy of BRG1/BRM antagonists, such as the inhibitor FHD-286 and the degrader AU15330, in overcoming resistance to menin inhibitors in AML with MLL rearrangement or mutant NPM1. The studies...
This $530,697 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Pennsylvania to investigate the use of protein arginine methyltransferase (PRMT) inhibitors for treating high-grade serous ovarian cancer and triple-negative breast cancer. The key objectives are to: 1) characterize the molecular mechanisms of PRMT inhibitor mono- and combination therapies, 2) evaluate the therapeutic potential of PRMT inhibitors in...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas Southwestern Medical Center (UT Southwestern) supports research into mechanisms of therapeutic resistance in cancer. The $449,196 award, which runs from April 1, 2025 to March 31, 2030, focuses on investigating how receptor tyrosine kinase (RTK) inhibition triggers rapid sumoylation of RTKs, leading to adaptative responses that drive secondary resistance to targeted...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
The federal Project Grant award of $1,144,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support research by the University of Texas MD Anderson Cancer Center to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma (CCRCC). The award period runs from September 1, 2025, through August 31, 2028. MD Anderson, a...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $676,584.00 to The University of Texas MD Anderson Cancer Center to conduct research on the co-evolution of cancer subclones and their tumor microenvironment in metastatic triple-negative breast cancer (MTNBC). The overarching goal is to expand the fundamental understanding of MTNBC metastasis by investigating the genomic and transcriptomic evolution of primary tumor cells and their...
The federal Project Grant award F31CA295091 is funded by the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program. The $119,922 award supports research to investigate the role of the Fanconi Anemia (FA) pathway in driving a chromosomal abnormality called chromothripsis, which is frequently observed in cancer genomes. The research aims to comprehensively identify regions of micronucleated chromosomes undergoing FA pathway processing during mitosis, and to...
The National Cancer Institute (NCI) awarded a $238,722 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, awarded on August 18, 2025, will fund research to investigate the role of mutagenic DNA repair mechanisms, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. The research aims to define the specific mechanisms by which...